Rithim Biologics®Inc. Presents at 2020 BIO International Convention Digital

June 5, 2020, MD, June 5, 2020--Rithim Biologics®, Inc. is honored to be presenting at and attending the 2020 BIO International Convention Digital within the NIH Innovation Zone, June 8-12.  Rithim’s co-Founders, Dr. Kevin Donahue and Ronald Anderson, will be presenting a 15-minute presentation on the company’s current efforts in delivering gene therapy to the heart.  Initial product development targets the prevention of atrial fibrillation in a post-operative setting (POAF).  POAF is an estimated $3 B burden on US healthcare and greater than $7 B on the world’s healthcare. Current products in development include the TheraKit inclusive of the cardiac gene therapy and either the SafeBrush for open heart applications or the DAAViS catheter system for less invasive cardiac surgical procedures.

Rithim Biologics® Adds World Class Talent to its Board of Directors with The Addition of Bob H. Katz

April 28, 2020

Woodbine, MD, Apr. 28, 2020--Rithim Biologics®, Inc. is pleased to announce the addition of Mr. Bob H. Katz to its Board of Directors effective March 1, 2020.

Bob is a proven serial life science start-up executive with a broad, multi-disciplinary background. He has excelled as an early stage specialist with unique R&D, Clinical, Regulatory and Operations successes. Mr. Katz’s background includes medical device and combination product (drug/device) development including implantables, durable medical equipment and disposables. He has been instrumental in successful PMA, IND, 510K and CE Marked product developments & regulatory approvals. His experiences span an impressive 36-year career in the fields of interventional cardiology, endovascular and vascular surgery, electrophysiology, ENT, women’s health & emergency medicine. Bob has a reputation for building effective and loyal teams and successful product introductions. He is self-driven with an entrepreneurial effort and venture fundraising experiences which have led to successful IPO and M&A outcomes. He is a named inventor on 20+ patents and has managed IP portfolios.  Mr. Katz has served on the Board of Directors at ContraMed LLC and PinPointe USA, Inc., and in senior executive roles at ContraMed, LLC, PinPointe USA, Inc., Aptus Endosystems, Revivant Corporation, and Symphonix Devices, Inc.  He is currently a Partner and Chief Technology Officer at Hybridge Medical, LLC.

Bob has earned his M.B.A. from the Friedt School of Business, Southeastern University; his M.S. in Biomedical Engineering from Boston University; a B.A. in Business Administration and a B.S. in Electrical Engineering both from Rutgers University.

“We are thrilled to have Bob bring his leadership and strategic and functional skills to our Board of Directors”, stated Ronald Anderson, Chairman.

Rithim Biologics®, Inc. is a privately held, early stage startup company developing surgical tools and kits for delivering gene therapies to treat tachycardias (fast heart rates) in humans.  Initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF) combining KCNH2-G628 gene therapy development with proprietary instrumentation and kits for efficacious delivery in humans.

For further information contact:

Ronald Anderson,